HC Wainwright Reiterates Buy Rating for Ocular Therapeutix

HC Wainwright has reiterated its buy rating for Ocular Therapeutix, Inc. (NasdaqGM: OCUL) with a price target of $25. This rating update was provided by analyst Yi Chen on June 18, 2026. The stock is currently trading around $9.64.

Ocular Therapeutix Stock Snapshot

Shares of Ocular Therapeutix are trading near $9.64. The company, which operates in the biotechnology sector, has a market capitalization of about $2.11 billion. Although it is not currently profitable, Ocular Therapeutix has a forward P/E ratio that is not meaningful due to negative earnings. The stock has experienced a 52-week low of $6.23 and a high of $16.44. Its 50-day moving average is approximately $9.00, while the 200-day moving average is around $10.53. The company maintains a strong liquidity position with a current ratio of 14.81 and a quick ratio of 14.49.

Recent Earnings

Ocular Therapeutix reported revenue of $52.04 million, showing a slight growth of 0.8%. However, the company currently has a negative return on equity of -68.55% and a net margin of 0.0%. The next earnings report is expected on August 5, 2026.

Insider Buying and Selling at Ocular Therapeutix, Inc.

On June 10, 2026, several insiders, including Adrienne Graves and Chief Financial Officer Jason Robins, purchased shares of Ocular Therapeutix. Graves acquired 44,000 shares, while Robins bought 14,024 shares. Other insiders, such as Seung Suh Hong and Richard Lindstrom, also made notable purchases on the same day.

Analysts Set New Price Targets

On June 18, 2026, HC Wainwright reiterated its buy rating for Ocular Therapeutix with a $25 price target. Baird also maintained a buy rating with a target of $30. RBC Capital had earlier reiterated a buy rating with a $30 target on May 6, 2026. The overall analyst consensus for Ocular Therapeutix is a strong buy, with a mean price target of $26 based on 11 analyst opinions.

About Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company based in Bedford, Massachusetts, specializing in therapies for retinal diseases and other eye conditions. The company uses its bioresorbable hydrogel-based formulation technology to develop products like DEXTENZA, a dexamethasone ophthalmic insert for post-surgical inflammation and pain, and AXPAXLI, an axitinib intravitreal hydrogel for treating eye diseases. Led by CEO Dr. Pravin U. Dugel, the company was founded in 2006 and employs around 325 people.

Bottom Line

HC Wainwright's reaffirmation of a buy rating with a $25 target reflects continued confidence in Ocular Therapeutix's potential. Investors typically watch these ratings closely, but it's important to remember that this analysis is based on past data and may not represent current market conditions. As always, 13F filings and analyst ratings like these are backward-looking.